Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198026
Dec 14, 2023 - bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
0
5 Big Drug Stocks That May Continue to Outperform in 2024
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
0
PBYI vs. VRTX: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2207091/pbyi-vs-vrtx-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2207091
Jan 08, 2024 - PBYI vs. VRTX: Which Stock Is the Better Value Option?
0
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
https://www.zacks.com/stock/news/2212227/biotech-stock-roundup-vrtx-crsp-gene-therapy-label-expansion-allk-falls-on-update?cid=CS-ZC-FT-analyst_blog|stock_roundup-2212227
Jan 18, 2024 - Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
0
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2214594/vertex-pharmaceuticals-vrtx-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2214594
Jan 23, 2024 - Vertex Pharmaceuticals (VRTX) reachead $439.70 at the closing of the latest trading day, reflecting a -0.09% change compared to its last close.
0
PBYI or VRTX: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2215148/pbyi-or-vrtx-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2215148
Jan 24, 2024 - PBYI vs. VRTX: Which Stock Is the Better Value Option?
0
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2217975/exelixis-exel-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2217975
Jan 30, 2024 - Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
https://www.zacks.com/stock/news/2256422/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2256422
Apr 16, 2024 - Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.
0
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
https://www.zacks.com/stock/news/2258650/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2258650
Apr 19, 2024 - Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
0
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685
Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
0